APP Pharmaceuticals (APPX) Receives Final Approval for Generic Kytril
More News related to APPX
- Mergent, Inc. Announces Changes to the HealthShares(TM) Cancer Index, Composite Index, Dermatology and Wound Care Index, Enabling Technologies Index, and Infectious Disease Index
- APP Pharmaceuticals and Fresenius Announce Clearance of APP Acquisition by U.S. Federal Trade Commission
- APP Pharmaceuticals Receives Manufacturing Approval for Three Product Codes of Heparin at Puerto Rico Facility
- APP Pharmaceuticals (APPX) Reports Slightly Higher Q2 Earnings; Issues Soft FY08 Guidance
- APP Pharmaceuticals Reports 2008 Second Quarter Net Revenues of $198 Million, Operating Income of $53 Million
More News related to FDA
- Orthofix International (OFIX) Receives FDA 510(k) Approval
- Rosetta Genomics (ROSG) Identifies Potential microRNA Biomarkers in Blood Serum
- BioCryst Pharma (BCRX) Reports Results From BCX-4208 Phase IIa Trial in Subjects With Psoriasis
- Celgene (CELG) Granted FDA Fast Track Designation for Amrubicin
- GTC Biotherapeutics (GTCB) Granted Priority Review from the FDA
APP Pharmaceuticals, Inc. (Nasdaq: APPX) received final approvals from the FDA of its Abbreviated New Drug Applications (ANDAs) for Granisetron Hydrochloride Injection, 1 mg/mL, 1 mL single dose, and 1mg/mL, 4mL multiple dose vials, the generic equivalent of Hoffmann-LaRoche's Kytril Injection.
Related Categories
FDAStocks Mentioned
-0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
